Literature DB >> 26840802

Therapeutic options in neuromyelitis optica spectrum disorders.

Joanna Kitley1, Jackie Palace2.   

Abstract

Neuromyelitis optica is a relapsing inflammatory disorder of the central nervous system that manifests predominantly with attacks of optic neuritis and longitudinally extensive transverse myelitis; attacks are often severe. In contrast to multiple sclerosis, a secondary progressive phase is rare, and disability in neuromyelitis optica spectrum disorders is related to relapses. Thus, prompt and effective treatment of relapses, and early initiation of long-term immunosuppression to prevent subsequent attacks is required in order to prevent morbidity and mortality.

Entities:  

Keywords:  AQP4-Ab; NMO; NMOSD; Neuromyelitis optica; aquaporin-4; neuromyelitis optica spectrum disorders; treatment

Mesh:

Substances:

Year:  2016        PMID: 26840802     DOI: 10.1586/14737175.2016.1150178

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  7 in total

1.  Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Authors:  Yael Hacohen; Yu Yi Wong; Christian Lechner; Maciej Jurynczyk; Sukhvir Wright; Bahadir Konuskan; Judith Kalser; Anne Lise Poulat; Helene Maurey; Esther Ganelin-Cohen; Evangeline Wassmer; Chery Hemingway; Rob Forsyth; Eva Maria Hennes; M Isabel Leite; Olga Ciccarelli; Banu Anlar; Rogier Hintzen; Romain Marignier; Jacqueline Palace; Matthias Baumann; Kevin Rostásy; Rinze Neuteboom; Kumaran Deiva; Ming Lim
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

Review 2.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

3.  Intravenous immunoglobulin as the rescue treatment in NMOSD patients.

Authors:  Jie Lin; Binbin Xue; Ruofan Zhu; Juyuan Pan; Jia Li; Yan Lin; Xiang Li; Junhui Xia
Journal:  Neurol Sci       Date:  2021-02-01       Impact factor: 3.307

Review 4.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

5.  Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.

Authors:  Jing Miao; Doreen E Aboagye; Boris Chulpayev; Lin Liu; Gary Ishkanian; Bangaruraju Kolanuvada; Dariush Alaie; Richard L Petrillo
Journal:  Am J Case Rep       Date:  2018-01-11

6.  CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Tianjiao Duan; Michael R Yeaman; Alan S Verkman
Journal:  J Neuroinflammation       Date:  2019-03-09       Impact factor: 8.322

7.  Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases.

Authors:  Maral Seyed Ahadi; Abdorreza Naser Moghadasi; Nasrin Asgari; Mohammad Ali Sahraian
Journal:  Caspian J Intern Med       Date:  2020
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.